1. Academic Validation
  2. Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors

Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors

  • J Med Chem. 2008 Apr 24;51(8):2447-56. doi: 10.1021/jm701384x.
Sheeba Varghese 1 Thulani Senanayake Tracey Murray-Stewart Kim Doering Alison Fraser Robert A Casero Jr Patrick M Woster
Affiliations

Affiliation

  • 1 Department of Pharmaceutical Sciences, Wayne State University, 259 Mack Avenue, Detroit, Michigan 48202, USA.
Abstract

A series of polyaminohydroxamic acids (PAHAs) and polyaminobenzamides (PABAs) were synthesized and evaluated as isoform-selective histone deacetylase (HDAC) inhibitors. These analogues contain a polyamine chain to increase affinity for chromatin and facilitate cellular import. Seven PAHAs inhibited HDAC >50% (1 microM), and two PABAs inhibited HDAC >50% (5 microM). Compound 17 increased acetylated alpha-tubulin in HCT116 colon tumor cells 253-fold but only modestly increased p21 (waf1) and acetylated histones 3 and 4, suggesting that 17 selectively inhibits HDAC 6. PABA 22 alone minimally increased p21 (waf1) and acetylated histones 3 and 4 but caused dose-dependent increases in p21 (waf1) in combination with 0.1 microM 5-azadeoxycytidine. Finally, 22 appeared to be a substrate for the polyamine transport system. None of these compounds were cytotoxic at 100 microM. PAHAs and PABAs exhibit strikingly different cellular effects from SAHA and have the potential for use in combination antitumor therapies with reduced toxicity.

Figures